Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
10-day high-dose vs 14-day standard-dose vonoprazan + amoxicillin dual therapy for Helicobacter pylori eradication
ChiCTR2600132909Phase 4Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of vonoprazan and amoxicillin in Helicobacter pylori infection (2 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Helicobacter pylori eradication rate. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
vonoprazanamoxicillin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2600132909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132909.